ArticleChembiochem : a European journal of chemical biology2026
A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry.Chembiochem : a European journal of chemical biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article is an initiative of the Chemical Biology in Industry Working Group of the "European Federation for Medicinal Chemistry and Chemical Biology (EFMC)" connecting discipline experts from several organizations across Europe. In the second half of 2025, we surveyed scientists from the listed organizations to collect precompetitive information on covalent hit identification and validation practices in the pharmaceutical industry. The questionnaire contained 33 questions and covered a broad spectrum of important aspects in covalent drug discovery, including target selection, library characteristics, hit identification, hit validation, and technical limitations. The results are shared and discussed in this article with the goal of generating best practices and providing insights into library design, hit identification, validation, and optimization in covalent drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.